| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2219SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-30328SS | |||
| Azide and BSA Free | NBP2-80712 | |||
HAF016). A specific band was detected for EGLN2/PHD1 at approximately 48 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8." alt="Western blot shows lysates of MDA-MB-231 human breast cancer cell line. PVDF Membrane was probed with 1 µg/mL of Human EGLN2/PHD1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6394) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for EGLN2/PHD1 at approximately 48 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8." class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF6394-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-76810SS | |||
| Azide and BSA Free | NBP2-80713 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-78782SS | |||
| Azide and BSA Free | NBP2-80714 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-05472SS | |||
HAF016). A specific band was detected for EGLN1/PHD2 at approximately 45-50 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." alt="Western blot shows lysates of human brain (cerebellum) tissue, human pancreas tissue, and human heart tissue. PVDF membrane was probed with 0.5 µg/mL of Sheep Anti-Human EGLN1/PHD2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF7680) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for EGLN1/PHD2 at approximately 45-50 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF7680-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-54676-25ul | |||
![<b>Genetic Strategies Validation. </b>Simple Western: EGLN1/PHD2 Antibody [NB100-137] - Simple Western lane view shows a specific band for PHD2/HIF Prolyl Hydroxylase 2 in 0.5 mg/mL of hypoxic HeLa cell lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Simple-Western-NB100-137-img0010.jpg)
![Western Blot: EGLN1/PHD2 Antibody [NB100-137] - Analysis of PHD2 expression in human prostate cancer cell lines. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Western-Blot-NB100-137-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: EGLN1/PHD2 Antibody [NB100-137] - Staining of endogenous PHD2 in U2OS cells. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-137-img0006.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: EGLN1/PHD2 Antibody [NB100-137] - Detection of PHD2 in human glioblastoma cell lysates. Image submitted by a verified customer review.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Western-Blot-NB100-137-img0005.jpg)
![Western Blot: EGLN1/PHD2 Antibody [NB100-137] - Detection of human PHD2 by Western blot. Recombinant epitope-tagged PHD1, PHD2 or PHD3 (10 ng/lane) or whole cell lysate from HeLa cells. EGLN1/PHD2 antibody used at 1 ug/mL. Detection by chemiluminescence.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Western-Blot-NB100-137-img0013.jpg)
![Flow Cytometry: EGLN1/PHD2 Antibody [NB100-137] - An intracellular stain was performed on Jurkat cells with NB100-137AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Flow-Cytometry-NB100-137-img0014.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: EGLN1/PHD2 Antibody [NB100-137] - Analysis of PHD2 in normoxia (lane 1) or hypoxia (lane 2) treated SK-N-BE(2) cells using anti-EGLN1/PHD2 antibody. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Western-Blot-NB100-137-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: EGLN1/PHD2 Antibody [NB100-137] - Staining of PHD2 in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-137-img0003.jpg)
![Immunohistochemistry: EGLN1/PHD2 Antibody [NB100-137] - Staining of lung vascular endothelium with EGLN1/PHD2 antibody. Image at 40X.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunohistochemistry-NB100-137-img0015.jpg)
![Flow Cytometry: EGLN1/PHD2 Antibody [NB100-137] - Detection of PHD2 in Jurkat cells. One million Jurkat cells were fixed, permeabilized, and stained with 3.0 ug/mL anti-EGLN1/PHD2 antibody in a 150 uL reaction. Isotype control (black), anti-MLL1 (red).](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Flow-Cytometry-NB100-137-img0007.jpg)
![Cellular localization of OS-9 & PHD2.(A) A lectin gel-shift assay was conducted to test for glycosylated proteins. Total cell lysates of U2OS cells were incubated in the presence or absence of the endoglycosidases EndoH & PNGaseF for 6 h at 37°C. Digest products were separated on a reducing 10% SDS-PAGE gel which contained concanavalin A co-polymerized in the top layer of the separating gel to retard mobility of glycosylated proteins [56]. Glycosylated OS-9 is indicated as ‘g’, deglycosylated OS-9 as ‘d’. (B) Detection of OS-9 & PHD2 in the nuclear fraction. HEK293 cells with & without transfection of the plasmid pcDNA3-OS-9 were separated into nuclear fraction (N) & postnuclear supernatant (PS), the latter containing cytoplasm & organelles. Western blot analysis included BiP, GAPDH & lamin A as typical marker proteins for the ER, the cytoplasm & the nucleus, respectively. (C) Detection of OS-9 & PHD2 in the cytoplasm. HEK293 cells were co-transfected with pcDNA3-OS-9 & pPHD2-V5. For hypoxia, cells were exposed to 3% O2 for 4 h. Cells were treated with 50 µg/ml digitonin & centrifuged to obtain a cytoplasmic (C) & an organelle fraction (O) & subjected to immunoblotting. (D) Isolation of cellular endomembranes. HEK293 cells were lysed mechanically by several passages through a 30½G needle. The postnuclear supernatant was processed further by ultra-centrifugation to separate the organelles (O) from the cytosol (C). High salt treatment (1 M KCl) of the organelle fraction produced a wash fraction (W) that contained dissociated peripheral membrane proteins. For immunoblot analysis of subcellular fractionations, cell aliquots were normalized for cell number prior to loading (B–D). Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-137_rabbit-polyclonal-egln1-phd2-antibody-210202423454817.jpg)
![Western Blot: EGLN1/PHD2 Antibody [NB100-137] - Representative picture of western blot in histopathologically unchanged tissue (N) & primary cancerous tissue (C) from patients with CRC. Immunodetection of bands was performed with Rp anti- PHD1, - PHD2, - PHD3 & - FIH Ab, followed by incubation with goat anti-rabbit HRP-conjugated Ab. The membrane was stripped & incubated with Rp anti-GAPDH Ab, followed by incubation with goat anti-rabbit HRP-conjugated Ab. Bands were revealed using SuperSignal West Femto Chemiluminescent Substrate, Thermo Fisher Scientific (Rockford, IL) & Biospectrum® Imaging System 500, UVP Ltd. (Upland, CA). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24195777), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-137_rabbit-polyclonal-egln1-phd2-antibody-310202415293310.jpg)
![Western Blot: EGLN1/PHD2 Antibody [NB100-137] - OS-9 shows no effect on regulation of HIF-1 alpha .Total cell lysates were used for SDS-PAGE & subsequent Western blotting. To generate nearly anoxic conditions, cells were exposed to an oxygen consuming chemical system or to 1% or 3% O2 for 4 h to generate hypoxia. (A) U2OS, HeLa & Hep3B cells were transiently transfected with the plasmid pOS-9-V5 48 h prior to the experiment. Lamin A & actin were used as loading controls. (B) U2OS cells were subjected to ER stress by incubation either with tunicamycin (1 µg/ml) or thapsigargin (0.5 µg/ml) for 20 h. To detect HIF-1 alpha under normoxia, cells were treated with DMOG (1 mM) for 4 h. A sample of DMSO-only treated cells was loaded to exclude unspecific side effects of the solvent. (C) U2OS cells were transduced with lentiviral construct pLKO.1-shRNA-OS-9 (shOS-9) mediating a stable knockdown of OS-9 expression. Control cells (c) were transduced with plasmid pLKO.1-puro. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-137_rabbit-polyclonal-egln1-phd2-antibody-31020241683931.jpg)
![Western Blot: EGLN1/PHD2 Antibody [NB100-137] - Oxygen chemotaxis is independent of the PHD/HIF pathway. a–dHIF1A, HIF2A, HIF1A+HIF2A & PHD2 CRISPR/Cas9 KO clones characterisation, respectively, regarding O2-directed migration. Left panels: immunoblot validation of HIF1A, HIF2A, HIF1A+HIF2A & PHD2 KO clones. To blot HIFs factors (a, b, c), cells were first pre-treated for 5 h with CoCl2 300 µM before protein extraction, a condition that promotes HIF factors accumulation (cf. Supplementary Fig. 8f). Middle panels: cell trajectories under confinement. Red dashed lines indicate the border of the cell cluster at 0 h. Right panels: relative distribution of MCF10A KO clones versus wt cells at the edge of the cluster at 48 h. These experiments demonstrate that HIF factors deletion does not prevent aerotaxis. e, f Tracks & redistribution of wt & PHD2 KO clone silenced for PHD3 (siPHD3) or not (siCTR). g Tracks & redistribution of MCF10A cells treated with DMOG (50 µM) or CoCl2 (50 µM) to inhibit PHDs, or with vehicle only (DMSO). These experiments demonstrate that PHDs do not participate in O2-sensing during aerotaxis. Confinement was applied for 48 h (a–g). Scale bars, 500 µm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30382089), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-137_rabbit-polyclonal-egln1-phd2-antibody-31020241612618.jpg)
![Western Blot: EGLN1/PHD2 Antibody [NB100-137] - PHD3 expression correlates with a mesenchymal-like morphology in pancreatic ductal adenocarcinoma cell lines.NHF-1 (Fibroblast) MiaPaca2, Panc1, CAPAN1 & BxPC3 cells were harvested for RNA & protein following 24 hours exposure to normoxia (21% O2) or hypoxia (1% O2). (A) Phase-contrast images at 10× magnification were taken of MiaPaca2 (mesenchymal-like) morphology & BxPC3 cells (differentiated, epithelial morphology) under normoxic conditions. (B) PHD3 mRNA expression was determined by qRT-PCR & graphed relative to BxPC3 in normoxia. All samples were normalized to 18S rRNA & graphed as expression relative to BxPC3-Vec Normoxia (lane 1). n = 3, error bars = 1 S.D. (C) Whole cell lysate was resolved by SDS-PAGE & blotted for beta -tubulin PHD3 & PHD2. N = normoxia, H = hypoxia (1% O2). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0083021), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-137_rabbit-polyclonal-egln1-phd2-antibody-310202415541942.jpg)
![Western Blot: EGLN1/PHD2 Antibody [NB100-137] - Iron supplementation restores HIF-1 alpha levels to normal following ATP6V0E1 inhibition in HeLa cells. (A) Schematic diagram of the multimeric V-ATPase complex. (B) Chemical inhibition of V-ATPase by 10 nM BafA treatment for 24 h, increased HIF-1 alpha levels in HIF alpha -GFPODD reporter cells. Treatment with 100 μM Fe (III) citrate significantly reduced the elevated HIF-1 alpha levels associated with loss of ATP6V0E1 (1 × 106 cells per sample harvested & analyzed; N = 2). (C) Knock-down of ATP6V0E1 subunit with three different CRISPR-Cas9 guides resulted in significant upregulation of HIF-1 alpha levels in HIF alpha -GFPODD reporter cells. Co-treating cells with 100 μM Fe (III) citrate led to a reduction in HIF-1 alpha levels across the three ATP6V0E1 depleted cells. phd2 was knocked down as a control & treatment with 100 μM Fe (III) citrate did not result in reduction of HIF-1 alpha levels (1 × 106 cells per sample harvested & analyzed; N = 2). FACs plot shown is a representative image of two biological repeats performed. (D) Immunoblot analysis for HIF-1 alpha & PHD2 levels in HIF alpha -GFPODD reporter cells with either ATP6V0E1 or PHD2 depleted or treated with 10 nM BafA. The cells were treated with 100 μM Fe (III) citrate for 24 h. beta actin was used as a control. Results validated findings observed by flow cytometry, whereby HIF-1 alpha levels were upregulated following ATP6V0E1 knock-down or inhibition & levels were re-normalized upon Fe (III) citrate treatment. Treatment of Fe (III) citrate in PHD2 depleted cells did not alter HIF-1 alpha levels. All experiments were performed in biological duplicate. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32984302), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-137_rabbit-polyclonal-egln1-phd2-antibody-310202415533838.jpg)
![Western Blot: EGLN1/PHD2 Antibody [NB100-137] - PHD3 depletion stabilizes hypoxic p27 expression by increasing p27 half-life. a Cell cycle arrest at G0 & subsequent release shows an increase of p27 expression in siPHD3 exposed cells. b Quantification for p27 expression under PHD3 depletion at indicated time points after cell cycle release in HeLa & 786-O cells. Asterisk indicates significant difference (p < 0,05; n = 3). c Cell cycle arrest at G0 & inhibition of protein synthesis with cycloheximide indicate increased p27 stability in PHD3 depleted HeLa cells. d Quantification of p27 expression using siPHD3 or control at indicated time points. Four independent experiments (± SEM) are shown (p < 0,05; n = 4). e Analysis of p27 stability in 786–0 cells by cycloheximide chase during reoxygenation after 24 h hypoxia demonstrates markedly increased half-life of p27 upon PHD3 depletion Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26223520), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-137_rabbit-polyclonal-egln1-phd2-antibody-310202415533825.jpg)
![Immunohistochemistry-Paraffin: EGLN1/PHD2 Antibody [NB100-2219] - Analysis of an FFPE mouse lung section using 1:200 dilution of EGLN1/PHD2 antibody. The staining was developed using HRP conjugated anti-rabbit secondary antibody and DAB reagent. The antibody generated a specific staining in the cytoplasm and nuclei of alveolar as well as bronchiolar epithelial cells. Cytoplasmic staining was observed in almost all cells while the nuclear positivity was seen in a subset of cells only.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunohistochemistry-Paraffin-NB100-2219-img0014.jpg)
![Western Blot: EGLN1/PHD2 Antibody [NB100-2219] - Detection of EGLN1/PHD2 in mouse kidney lysate. ECL exposure, 20 seconds.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Western-Blot-NB100-2219-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: EGLN1/PHD2 Antibody [NB100-2219] - EGLN1/PHD2 antibody at 1:500 in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2219-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: EGLN1/PHD2 Antibody [NB100-2219] - Analysis of EGLN1/PHD2 in ARPE-19 cells using anti-PHD2 antibody. ICC/IF image submitted by a veriifed customer review.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2219-img0009.jpg)
![Immunohistochemistry: EGLN1/PHD2 Antibody [NB100-2219] - Staining of renal tubular epithelium in mouse using NB100-2219 at 2.5 ug/mL.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunohistochemistry-NB100-2219-img0010.jpg)
![Western Blot: EGLN1/PHD2 Antibody (366G/76/3) [NBP1-30328] - Aanalysis in HeLa whole cell extracts using EGLN1/PHD2 antibody NBP1-30328.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-366G-76-3-Western-Blot-NBP1-30328-img0004.jpg "Western Blot: EGLN1/PHD2 Antibody (366G/76/3) [NBP1-30328] - Aanalysis in HeLa whole cell extracts using EGLN1/PHD2 antibody NBP1-30328.")
![Immunohistochemistry: EGLN1/PHD2 Antibody (366G/76/3) [NBP1-30328] - Analysis of PHD2 in human renal cancer using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-366G-76-3-Immunohistochemistry-NBP1-30328-img0005.jpg)
![Simple Western: EGLN1/PHD2 Antibody (366G/76/3) [NBP1-30328] - Lane view shows a specific band for EGLN1/PHD2 in 0.5 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-366G-76-3-Simple-Western-NBP1-30328-img0006.jpg)
![Immunohistochemistry-Paraffin: EGLN1/PHD2 Antibody (2445B) [NBP2-76810] - EGLN1/PHD2 was detected in immersion fixed paraffin-embedded sections of human kidney using Rabbit Anti-EGLN1/PHD2 Monoclonal Antibody (Catalog #NBP2-76810) at 3 ug/mL for 1 hour at room temperature followed by incubation with the Anti-Rabbit IgG VisUCyt(TM) HRP Polymer Antibody (Catalog # VC003). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell cytoplasm and nuclei.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-2445B-Immunohistochemistry-Paraffin-NBP2-76810-img0003.jpg "Immunohistochemistry-Paraffin: EGLN1/PHD2 Antibody (2445B) [NBP2-76810] - EGLN1/PHD2 was detected in immersion fixed paraffin-embedded sections of human kidney using Rabbit Anti-EGLN1/PHD2 Monoclonal Antibody (Catalog #NBP2-76810) at 3 ug/mL for 1 hour at room temperature followed by incubation with the Anti-Rabbit IgG VisUCyt(TM) HRP Polymer Antibody (Catalog # VC003). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell cytoplasm and nuclei.")
![Western Blot: EGLN1/PHD2 Antibody (2445B) [NBP2-76810] - Total protein from human HeLa, THP-1 and U87 cell lines was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-PHD2 antibody in block buffer and detected with an anti-rabbit HRP secondary antibody using West Pico PLUS chemiluminescence detection reagent.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-2445B-Western-Blot-NBP2-76810-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: EGLN1/PHD2 Antibody (2445B) [NBP2-76810] - EGLN1/PHD2 was detected in immersion fixed WM-115 human malignant melanoma cell line using Rabbit Anti-EGLN1/PHD2 Monoclonal Antibody (Catalog # NBP2-76810) at 3 ug/mL for 3 hours at room temperature. Cells were stained using the NorthernLight(TM) 557-conjugated Anti-Rabbit IgG secondary antibody (red; Catalog # NL004) and counterstained with DAPI (blue). Specific staining was localized to cell cytoplasm and nuclei.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-2445B-Immunocytochemistry-Immunofluorescence-NBP2-76810-img0002.jpg)
![Flow Cytometry: EGLN1/PHD2 Antibody (2445B) [NBP2-76810] - Human Jurkat T Cell Leukemia Cell Line was stained with Rabbit anti-EGLN1/PHD2 Monoclonal Antibody (Catalog # NBP2-76810, filled histogram) or Rabbit IgG Isotype Control Antibody (Catalog # MAB1050, open histogram) followed by Phycoerythrin-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # F0110). To facilitate intracellular staining, cells were fixed and permeabilized with FlowX FoxP3 Fixation & Permeabilization Buffer Kit (Catalog # FC012).](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-2445B-Flow-Cytometry-NBP2-76810-img0001.jpg)
![Western Blot: EGLN1/PHD2 Antibody (2445D) [NBP2-78782] - Western blot shows lysates of PC3 human prostate cancer cell line, HEK293T human embryonic kidney cell line, and NIH3T3 mouse embryonic fibroblast cell line. PVDF membrane was probed with 1 ug/mL of Rabbit Anti-Human/Mouse EGLN1/PHD2 Monoclonal Antibody (Catalog # NBP2-78782) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for EGLN1/PHD2 at approximately 50 kDa (as indicated). This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-2445D-Western-Blot-NBP2-78782-img0001.jpg "Western Blot: EGLN1/PHD2 Antibody (2445D) [NBP2-78782] - Western blot shows lysates of PC3 human prostate cancer cell line, HEK293T human embryonic kidney cell line, and NIH3T3 mouse embryonic fibroblast cell line. PVDF membrane was probed with 1 ug/mL of Rabbit Anti-Human/Mouse EGLN1/PHD2 Monoclonal Antibody (Catalog # NBP2-78782) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for EGLN1/PHD2 at approximately 50 kDa (as indicated). This experiment was conducted under reducing conditions.")
![Immunohistochemistry-Paraffin: EGLN1/PHD2 Antibody (2445D) [NBP2-78782] - EGLN1/PHD2 was detected in immersion fixed paraffin-embedded sections of human kidney using Rabbit Anti-Human/Mouse EGLN1/PHD2 Monoclonal Antibody (Catalog # NBP2-78782) at 3 ug/mL for 1 hour at room temperature followed by incubation with an anti-rabbit secondary antibody.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-2445D-Immunohistochemistry-Paraffin-NBP2-78782-img0002.jpg)
![Western Blot: EGLN2/PHD1 Antibody [NBP3-05472] - Total protein from human HeLa, K562, HepG2 and U87 cells was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-EGLN2/PHD1 (NBP2-59179) in blocking buffer and detected with an anti-rabbit HRP secondary antibody using NovaLume chemiluminescence detection reagent (NPB2-61915).](http://images.novusbio.com/fullsize/EGLN2-PHD1-Antibody-Western-Blot-NBP3-05472-img0001.jpg "Western Blot: EGLN2/PHD1 Antibody [NBP3-05472] - Total protein from human HeLa, K562, HepG2 and U87 cells was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-EGLN2/PHD1 (NBP2-59179) in blocking buffer and detected with an anti-rabbit HRP secondary antibody using NovaLume chemiluminescence detection reagent (NPB2-61915).")
![Immunocytochemistry/Immunofluorescence: EGLN2/PHD1 Antibody [NBP3-05472] - HeLa cells were fixed for 10 minutes using 4% PFA and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton-X100. The cells were incubated with anti-EGLN2/PHD1 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/EGLN2-PHD1-Antibody-Immunocytochemistry-Immunofluorescence-NBP3-05472-img0002.jpg)
![Recombinant Human EGLN1/PHD2 GST (N-Term) Protein [H00054583-P01] - Analysis by 12.5% SDS-PAGE. Gel stained with Coomassie Blue.](http://images.novusbio.com/fullsize/qc_test-H00054583-P01-1.jpg "Recombinant Human EGLN1/PHD2 GST (N-Term) Protein [H00054583-P01] - Analysis by 12.5% SDS-PAGE. Gel stained with Coomassie Blue.")
![Immunocytochemistry/Immunofluorescence: EGLN1/PHD2 Antibody [NBP2-54676] - Immunofluorescent staining of human cell line U-251 MG shows localization to cytosol.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-54676-img0003.jpg "Immunocytochemistry/Immunofluorescence: EGLN1/PHD2 Antibody [NBP2-54676] - Immunofluorescent staining of human cell line U-251 MG shows localization to cytosol.")
![Immunohistochemistry-Paraffin: EGLN1/PHD2 Antibody [NBP2-54676] - Staining of human colon shows strong cytoplasmic positivity in glandular cells.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunohistochemistry-Paraffin-NBP2-54676-img0001.jpg)
